Occluded Artery Trial (OAT)

This study is testing the hypothesis that opening an occluded artery post Myocardial Infarction (3-28 days post MI) in high-risk, asymptomatic patients results in improved patient outcomes over a three year follow-up period. For this complex study, MMRI serves as the Data Coordinating Center (DCC) and provides the statistical design, power calculations, and generation of performance data to assess treatment effects for the Data and Safety Monitoring Board.

Silent Infarction Transfusion Trial in Children (SITT)

Silent cerebral infarctions are the most common cause of severe neurological disease in children with sickle cell anemia. These events occur in 20% of children with sickle cell anemia prior to their 12th birthday. MMRI is managing all aspects of this trial in investigating whether blood transfusion therapy decreases further neurologic deterioration in children experiencing silent cerebral infarcts.

Treating Hepatitis C in Children (PEDS-C)

Hepatitis C virus infection is a global health problem that causes progressive liver damage, including cirrhosis of the liver, hepatic failure, and cancer, frequently requiring liver transplantation. In children, the virus is particularly insidious. This study is assessing the safety and efficacy of a new version of interferon alpha-2a developed by Roche Laboratories for the treatment of chronic hepatitis C virus in children. FDA requirements are particularly cautious and stringent when trials involve children. MMRI procedures and highly experienced personnel work closely with all involved parties to ensure the highest quality and safety possible for the involved children.

Persantine and Aspirin in Coronary Heart Disease (PARIS)

The Persantine-Aspirin Reinfarction Study was a controlled, randomized, double-blind trial designed to assess the effects of the combination of Persantine (dipyridamole) plus aspirin compared with the effects of aspirin alone and with placebo on mortality and morbidity in persons with previous myocardial infarction (MI). The scientific foundation for the trial stemmed from the extensive data showing that blood platelets play a key role in thrombus formation in atherosclerotic arteries, and possibly atherogenesis as well, and from the findings on the ability of the drugs under study to influence platelet function in a way possibly impeding thrombogenesis and atherogenesis.